In this regard many drugs can modulate this ratio with therapeutic implications for patients with obesity and diabetes: insulin reduces ACE2 expression, but GLP-1 agonists, pioglitazone, ACE inhibitors, and statins upregulate ACE2, reducing the ACE/ACE2 ratio [38–44]. This evidence concerns the gene ACE and obesity due to melanocortin 4 receptor deficiency.